Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in squamous cell carcinoma of the vulva
NCT00476476Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2006
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in vulvar squamous cell carcinoma (VSCC), sponsored by Dana-Farber Cancer Institute. Started Dec 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT00476476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00476476.